The companies shared aging clock data from semaglutide and tirzepatide trials at a conference. Geneticist Steve Horvath called a two year effect strong.
Recap by typeshit. Full story at New York Post.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Christina DiArcangelo points out that GLP-1 drugs now come in different versions for weight loss and metabolic health, and argues they shouldn't be treated as interchangeable.
FitPeo frames Ozempic, Zepbound and other GLP-1s as a useful tool rather than a fix, and stresses pairing them with solid eating habits.
Loading…